MARKSANSMarksans Pharma Limited
Pharma · Drug Manufacturers - General · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Revenue growth: 20.8% YoY
- • Profit growth: 63.5% YoY
- • Debt/Equity: 0.11
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • 3-month return: +15.6%
Bull case
- • Revenue growth: 20.8% YoY
- • Profit growth: 63.5% YoY
- • Debt/Equity: 0.11
- • Price vs SMA200: above
Bear case
- • Dividend yield: 0.22%
- • RSI: 40
- • MACD: bearish
- • 1-month return: -12.1%
Key risks
- • Dividend yield: 0.22%
- • RSI: 40
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹11.83). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.